Gapping up
In reaction to earnings/guidance:
- SKX +9.3%, SAM +8.3%, MAT +6.2%, SNAP +4.9%, BJRI +4.3%, ALV +4.1%, HTH +3.8%, SIVB +3.5%, BHR +3.1%, CE +3%, VICR +3%, WWE +2%, RF +2%, SXT +2%, OZK +1.7%, SLB +1.4%, CAMP +1.3%, KN +1.2%
Other news:
- SLAB +18.1% (SWKS to acquire the Infrastructure & Automotive business of SLAB for $2.75 bln)
- EBSB +12.2% (INDB to acquire EBSB)
- DMTK +9.1% (launches DermTech PLAplus for early detection of melanoma)
- SKLZ +8.8% (Cathie Wood's Arkk investment purchased 122K shares yesterday)
- SD +4.9% (acquires overriding royalty interest assets of SandRidge Mississippian Trust for $4.85 mln)
- SWKS +4.1% (SWKS to acquire the Infrastructure & Automotive business of SLAB for $2.75 bln)
- ANAB +3% (FDA approves GSK's Biologics License Application for JEMPERLI)
- NVAX +2.2% (reports Phase 2b trial results published in The Lancet)
- OLED +1.8% (extends long-term OLED agreements with Visionox)
- ILMN +1.6% (ILMN and Kartos Therapeutics announce deal to co-develop a TP53 companion diagnostic)
Analyst comments:
- MAX +2.4% (upgraded to Overweight from Neutral at JP Morgan)
- OVV +1.5% (upgraded to Outperform from Peer Perform at Wolfe Research)
- MRO +1.3% (upgraded to Outperform from Peer Perform at Wolfe Research)
- AAL +1% (upgraded to Mkt Perform from Underperform at Raymond James)